Bowles Kristian M, Warner Brian A, Baglin Trevor P
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Br J Haematol. 2006 Oct;135(2):198-200. doi: 10.1111/j.1365-2141.2006.06246.x. Epub 2006 Aug 25.
Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.
血小板量（平均血小板体积×血小板计数）可从常规全血细胞计数获得的数据得出，在诊断时可将骨髓增生异常综合征（MDS）患者分为三个不同的预后组：低血小板量组——中位生存期5个月，5年生存率0%；中等血小板量组——中位生存期30个月，5年生存率34%；高血小板量组——中位生存期在82个月随访时未达到，5年生存率82%。这些数据为MDS诊断时提供了一个简单快速的预后指标。
